A detailed history of Vanguard Group Inc transactions in Kezar Life Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,741,105 shares of KZR stock, worth $17.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,741,105
Previous 2,741,105 -0.0%
Holding current value
$17.7 Million
Previous $1.64 Million 28.35%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.6 - $0.92 $211,871 - $324,869
-353,119 Reduced 11.41%
2,741,105 $1.64 Million
Q1 2024

May 10, 2024

BUY
$0.8 - $1.05 $24,592 - $32,277
30,740 Added 1.0%
3,094,224 $2.78 Million
Q4 2023

Feb 14, 2024

BUY
$0.72 - $1.15 $16,500 - $26,354
22,917 Added 0.75%
3,063,484 $2.91 Million
Q3 2023

Nov 14, 2023

BUY
$1.08 - $2.54 $8,096 - $19,042
7,497 Added 0.25%
3,040,567 $3.62 Million
Q2 2023

Aug 14, 2023

BUY
$2.31 - $3.06 $48,403 - $64,119
20,954 Added 0.7%
3,033,070 $7.43 Million
Q1 2023

May 15, 2023

SELL
$3.13 - $7.31 $43,403 - $101,367
-13,867 Reduced 0.46%
3,012,116 $9.43 Million
Q4 2022

Feb 10, 2023

BUY
$6.39 - $8.8 $209,438 - $288,428
32,776 Added 1.1%
3,025,983 $21.3 Million
Q3 2022

Nov 14, 2022

BUY
$7.99 - $10.75 $4.44 Million - $5.98 Million
556,020 Added 22.81%
2,993,207 $25.8 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $17.13 $957,691 - $3.58 Million
209,103 Added 9.38%
2,437,187 $20.2 Million
Q1 2022

May 13, 2022

BUY
$12.3 - $18.33 $4.14 Million - $6.17 Million
336,669 Added 17.8%
2,228,084 $37 Million
Q4 2021

Feb 14, 2022

SELL
$7.44 - $16.72 $189,228 - $425,256
-25,434 Reduced 1.33%
1,891,415 $31.6 Million
Q3 2021

Nov 12, 2021

BUY
$4.85 - $9.73 $58,471 - $117,304
12,056 Added 0.63%
1,916,849 $16.6 Million
Q2 2021

Aug 13, 2021

BUY
$4.93 - $6.46 $9.39 Million - $12.3 Million
1,904,793 New
1,904,793 $10.3 Million

Others Institutions Holding KZR

About Kezar Life Sciences, Inc.


  • Ticker KZR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,369,504
  • Market Cap $440M
  • Description
  • Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...
More about KZR
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.